Inhibikase Therapeutics paid its 4 named executives $44.4M in total in FY2025 (Dec). CEO Mark Iwicki was paid $30.6M of that.
Pay$100 in the stock at the end of FY24 → $63
Pay of each named executive
Mark IwickiChief Executive Officer and Director
| FY2025 (Dec) |
1 year
Chris Cabell, M.D.President and Head of Research and Development
| FY2025 (Dec) |
1 year
David McIntyreChief Financial Officer
| FY2025 (Dec) |
1 year
Milton H. Werner, Ph.D.Former President and Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.